Drug reimbursement and GPs' prescribing decisions: A randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: How GPs react to drug reimbursement

Fundamental and Clinical Pharmacology

Volumn 24, Issue 4, 2010, Pages 509-516

  Verger, Pierre ^a,b,c   Rolland, Sophie ^a,c   Paraponaris, Alain ^a,b,c   Bouvenot, Julien ^b   Ventelou, Bruno ^a,b,c,d  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d CNRS   (France)

Author keywords

general practitioners; medical information; prescription; reimbursement; rimonabant

Indexed keywords

RIMONABANT;

ADULT; ARTICLE; FEMALE; GENERAL PRACTITIONER; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE PRACTICE; REIMBURSEMENT;

ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; FRANCE; GENERAL PRACTITIONERS; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; MALE; OBESITY; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; REIMBURSEMENT MECHANISMS;

EID: 77954412551     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00779.x     Document Type: Article

References (31)

1. Greving J.P., Denig P., van der Veen W.J., Beltman F.W., Sturkenboom M.C., Haaijer-Ruskamp F.M. Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Soc. Sci. Med. (2006) 63 2890 2898. (Pubitemid 44584502)
2. McGavock H., Webb C.H., Johnston G.D., Milligan E. Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators. BMJ (1993) 307 1118 1120. (Pubitemid 23313211)
3. Reichert S., Simon T., Halm E.A. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch. Intern. Med. (2000) 160 2799 2803.
4. French National Authority for Health, Data on file, French Health Products Safety Agency. Which role for Rimonabant (Acomplia) in obesity or overweight? (2007) http://www.afssaps.fr/content/download/11905/142631/version/ 2/file/fiche-bon-usage-acomplia.pdf [accessed 2008 July 3].
5. Basdevant A., Laville M., Ziegler O. Recommendations for the diagnosis, the prevention and the treatment of obesity. Diabetes Metab. (2002) 28 146 150. (Pubitemid 34437408)
6. National Institute for Health and Clinical Excellence, Data on file, Rimonabant for the treatment of overweight and obese adults 2008) http://www.nice.org.uk/guidance/index.jsp?action=article&o=38515#seven. [Accessed 2008 July 11].
7. Lau D.C., Douketis J.D., Morrison K.M., Hramiak I.M., Sharma A.M., Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ (2007) 176 S1 S13.
8. Hassell K., Atella V., Schafheutle E.I., Weiss M.C., Noyce P.R. Cost to the patient or cost to the healthcare system? Which one matters the most for GP prescribing decisions? A UK-Italy comparison. Eur. J. Public Health (2003) 13 18 23. (Pubitemid 36356421)
9. Ryan M., Birch S. Charging for health care: evidence on the utilisation of NHS prescribed drugs. Soc. Sci. Med. (1991) 33 681 687.
10. Prosser H., Walley T. A qualitative study of GPs' and PCO stakeholders' views on the importance and influence of cost on prescribing. Soc. Sci. Med. (2005) 60 1335 1346. (Pubitemid 40038762)
11. Allery L.A., Owen P.A., Robling M.R. Why general practitioners and consultants change their clinical practice: a critical incident study. BMJ (1997) 314 870 874.
12. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA (2000) 283 373 380. (Pubitemid 30051756)
13. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can. Fam. Physician (1997) 43 941 945. (Pubitemid 127776791)
14. Verger P., Arnaud S., Ferrer S. et al. Inequities in reporting asbestos-related lung cancer: influence of smoking stigma and physician's specialty, workload and role perception. Occup. Environ. Med. (2008) 65 392 397. (Pubitemid 351775799)
15. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA (2006) 295 761 775. (Pubitemid 43244304)
16. OVP-Vidal. The 2008 VIDAL Drug Compendium. The reference for drug information. Vidal, Paris, France. 2008.
17. Bocquier A., Verger P., Basdevant A. et al. Overweight and obesity: knowledge, attitudes, and practices of general practitioners in france. Obes. Res. (2005) 13 787 795.
18. Campbell K., Engel H., Timperio A., Cooper C., Crawford D. Obesity management: Australian general practitioners' attitudes and practices. Obes. Res. (2000) 8 459 466. (Pubitemid 30339267)
19. Fogelman Y., Vinker S., Lachter J., Biderman A., Itzhak B., Kitai E. Managing obesity: a survey of attitudes and practices among Israeli primary care physicians. Int. J. Obes. Relat. Metab. Disord. (2002) 26 1393 1397. (Pubitemid 35221889)
20. Price J.H., Desmond S.M., Krol R.A., Snyder F.F., O'Connell J.K. Family practice physicians' beliefs, attitudes, and practices regarding obesity. Am. J. Prev. Med. (1987) 3 339 345. (Pubitemid 18018424)
21. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. J. Clin. Pharm. Ther. (2008) 33 1 10.
22. Artz M.B., Hadsall R.S., Schondelmeyer S.W. Impact of generosity level of outpatient prescription drug coverage on prescription drug events and expenditure among older persons. Am. J. Public Health (2002) 92 1257 1263.
23. Atella V. Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price. Health Policy (2000) 50 197 218. (Pubitemid 30072736)
24. Haaijer-Ruskamp F.M. Experiences with patient charges. Int. J. Risk Saf. Med. (2002) 15 93 96.
25. Kasje W.N., Timmer J.W., Boendermaker P.M., Haaijer-Ruskamp F.M. Dutch GPs' perceptions: the influence of out-of-pocket costs on prescribing. Soc. Sci. Med. (2002) 55 1571 1578.
26. Starmans B., Janssen R., Schepers M., Verkooijen M. The effect of a patient charge and a prescription regulation on the use of antihypertension drugs in Limburg, The Netherlands. Health Policy (1994) 26 191 206. (Pubitemid 24087605)
27. Caudill T.S., Johnson M.S., Rich E.C., McKinney W.P. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch. Fam. Med. (1996) 5 201 206. (Pubitemid 126445103)
28. Ziegler M.G., Lew P., Singer B.C. The accuracy of drug information from pharmaceutical sales representatives. JAMA (1995) 273 1296 1298.
29. Caamano F., Figueiras A., Gestal-Otero J.J. Influence of commercial information on prescription quantity in primary care. Eur. J. Public Health (2002) 12 187 191.
30. Pollock K., Grime J. The cost and cost-effectiveness of PPIs - GP perspectives and responses to a prescribing dilemma and their implications for the development of patient-centred healthcare. Eur. J. Gen. Pract. (2003) 9 126 133. (Pubitemid 38035242)
31. Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002. Morb. Mortal. Wkly Rep. (2004) 53 1066 1068.